TYK Medicines, Inc (HKG:2410)

Market Cap	3.67B -63.3%
Revenue (ttm)	n/a
Net Income	-333.58M
EPS	-0.89
Shares Out	384.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,083,500
Average Volume	1,932,700
Open	9.68
Previous Close	9.55
Day's Range	9.54 - 9.74
52-Week Range	9.20 - 33.50
Beta	n/a
RSI	32.81
Earnings Date	Jun 1, 2026

About TYK Medicines

TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor to treat solid tumors, including b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 173
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2410

Financial Performance

Financial numbers in CNY